Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gomez RG, Baste-Rotllan N, Bidault F, Guigay J, Le Tourneau C, Saada-Bouzid E, Even C. Saleh K, et al. Among authors: le tourneau c. Eur J Cancer. 2019 Nov;121:123-129. doi: 10.1016/j.ejca.2019.08.026. Epub 2019 Sep 28. Eur J Cancer. 2019. PMID: 31574417
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Cassier PA, Italiano A, Gomez-Roca C, Le Tourneau C, Toulmonde M, D'Angelo SP, Weber K, Loirat D, Jacob W, Jegg AM, Michielin F, Christen R, Watson C, Cannarile M, Klaman I, Abiraj K, Ries CH, Weisser M, Rüttinger D, Blay JY, Delord JP. Cassier PA, et al. Among authors: le tourneau c. Eur J Cancer. 2020 Dec;141:162-170. doi: 10.1016/j.ejca.2020.09.038. Epub 2020 Nov 5. Eur J Cancer. 2020. PMID: 33161240 Free article. Clinical Trial.
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
Sablin MP, Gestraud P, Jonas SF, Lamy C, Lacroix-Triki M, Bachelot T, Filleron T, Lacroix L, Tran-Dien A, Jézéquel P, Mauduit M, Barros Monteiro J, Jimenez M, Michiels S, Attignon V, Soubeyran I, Driouch K, Servant N, Le Tourneau C, Kamal M, André F, Bièche I. Sablin MP, et al. Among authors: le tourneau c. Br J Cancer. 2024 Oct;131(6):1060-1067. doi: 10.1038/s41416-024-02804-6. Epub 2024 Aug 2. Br J Cancer. 2024. PMID: 39090361 Free PMC article.
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. Bellera CA, et al. Among authors: le tourneau c. Eur J Cancer. 2013 Mar;49(4):769-81. doi: 10.1016/j.ejca.2012.09.035. Epub 2012 Nov 2. Eur J Cancer. 2013. PMID: 23122780
284 results